Previous Close | 38.13 |
Open | 38.22 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 37.51 - 38.37 |
52 Week Range | 25.17 - 42.44 |
Volume | |
Avg. Volume | 312,046 |
Market Cap | 546.141M |
Beta (5Y Monthly) | 1.20 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.09 |
Earnings Date | Nov 06, 2024 - Nov 11, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 43.00 |
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
EDEN PRAIRIE, Minn., October 01, 2024--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ XL Thrombectomy System.